$LH

Kyle Kathryn W sold $201K of LH

Kyle Kathryn W (EVP, Chief Legal Officer) sold 762 shares of LABCORP HOLDINGS INC. (LH) at $263.89 ($0.20M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kyle Kathryn W
Published Jun 10, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider activity (officer sale) but does not include any operational, financial, or regulatory development.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable as a fundamental catalyst.

03

What to watch

The filing does not reveal reasons for sale, and the transaction size (~$201K) is modest relative to typical market capitalization, limiting signal strength.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10; sale executed 2026-06-08.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for LABCORP HOLDINGS INC. (LH).

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

SEC Form 4 shows LH officer Kyle Kathryn W sold 762 shares for ~$201K on a Rule 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any impact would be short-lived and sentiment-driven.

Evidence & confidence

The disclosure is an officer sale (not a purchase) and explicitly states a pre-arranged 10b5-1 plan, which usually reduces interpretive value versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated officer selling can coincide with internal risk management or diversification needs; traders may still watch for follow-on insider activity.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure (LH).

  • Kyle Kathryn W

    EVP, Chief Legal Officer; sold 762 shares on 2026-06-08 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.